Advance Treatment
- Business
Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
Osaka, Japan: − Seven Year Data Reinforce Long-term Efficacy and Safety Review of ADVATE (Antihemophilic Factor [Recombinant]) − Abstracts Support…
Read More »